Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 10:15 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2905–2928 of 145,503 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Disorders Clear all

Conditions: Obesity, Metabolic Disease, Metabolic Syndrome, Insulin Sensitivity, Insulin Resistance, Weight Loss
Interventions: MICT Exercise, No Exercise (Control); Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 40 Years
Enrollment: 68 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Hypertriglyceridemia
Interventions: CaPre, Placebo; Drug
Lead sponsor: Grace Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 278 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 53
States / cities: Birmingham, Alabama • Childersburg, Alabama • Encino, California + 44 more

Conditions: Major Depression
Interventions: Problem Solving Therapy, Engage; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 60 Years and older
Enrollment: 262 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 2
States / cities: White Plains, New York • Seattle, Washington

Conditions: Telemetry Usage, Chest Pain, Unstable Angina, Resource Utilization
Interventions: Telemetry, Unmonitored; Other
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Cancer Survivorship, Sleep Disturbances
Interventions: Latin Dance; Behavioral
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New Brunswick, New Jersey

Conditions: Multiple Myeloma
Interventions: Ixazomib; Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Cardiac Arrhythmias
Interventions: EluPro Antibiotic-Eluting BioEnvelope; Combination Product
Lead sponsor: Elutia Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 4
States / cities: La Jolla, California • Tallahassee, Florida • Boston, Massachusetts + 1 more

Conditions: Ocular Injury
Interventions: Artificial Tears; Drug
Lead sponsor: Ocular Therapeutix, Inc.; Industry
Eligibility: Not listed
Enrollment: 300 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Sioux Falls, South Dakota

Conditions: Breast Cancer
Interventions: iMETX intervention; Behavioral
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 4
States / cities: Carmel, Indiana • Indianapolis, Indiana

Conditions: Osteonecrosis
Interventions: Ixmyelocel-T, Standard of Care Only; Biological · Other
Lead sponsor: Vericel Corporation; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 3
States / cities: Baltimore, Maryland • Minneapolis, Minnesota • Brooklyn, New York

Conditions: Parkinson's Disease
Interventions: Deep Brain Stimulation; Device
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Diabetes Mellitus, Type 2
Interventions: exenatide, rosiglitazone; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 19
States / cities: Phoenix, Arizona • San Francisco, California • Jacksonville, Florida + 16 more

Conditions: HIV Infections
Interventions: Adefovir dipivoxil; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Stroke, Cerebral Infarction, Atherosclerosis, Constriction, Pathologic
Interventions: Warfarin, Aspirin; Drug
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 40 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 2003
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Premature Newborn, Necrotizing Enterocolitis
Interventions: Citrulline samples; Diagnostic Test
Lead sponsor: University of Miami; Other
Eligibility: Not listed
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Lung Cancer, Perioperative/Postoperative Complications, Pulmonary Complications, Tobacco Use Disorder
Interventions: exercise intervention, smoking cessation intervention, counseling intervention, educational intervention, conventional surgery, pulmonary complications management/prevention; Behavioral · Other · Procedure
Lead sponsor: Mayo Clinic; Other
Eligibility: 40 Years to 120 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Ovarian Epithelial Tumor, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions: Laboratory Biomarker Analysis, Veliparib; Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 52 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 153
States / cities: Phoenix, Arizona • Concord, California • La Jolla, California + 114 more

Conditions: Niemann-Pick Disease, Type C
Interventions: Not listed
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: 3 Months and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Urethral Cancer, Transitional Cell Carcinoma of the Bladder, Ureter Cancer
Interventions: arsenic trioxide; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2000
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Hematopoietic Organs; Disorder
Interventions: Lactobacillus plantarum strains 299 and 299v; Drug
Lead sponsor: Columbia University; Other
Eligibility: 2 Years to 17 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 3
States / cities: Jacksonville, Florida • St. Petersburg, Florida • New York, New York

Conditions: Healthy Subjects
Interventions: TI Inhalation Powder; Drug
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 13 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Baclofen Withdrawal Syndrome
Interventions: Oral baclofen, Intervenous baclofen; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Lymphoma
Interventions: autologous immunoglobulin idiotype-KLH conjugate vaccine, sargramostim; Biological
Lead sponsor: Favrille; Industry
Eligibility: 18 Years and older
Enrollment: 238 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 51
States / cities: Birmingham, Alabama • Beverly Hills, California • La Jolla, California + 43 more

Conditions: Thoracic Diseases, Cardiovascular Diseases
Interventions: Videofluoroscopic swallow exam with concurrent monitoring of respiratory-swallow coordination; Diagnostic Test
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 90 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 1
States / cities: Gainesville, Florida

Search by objective public record fields.

Metabolic Adaptations to Weight Loss With and Without Exercise

A Phase 3 STudy of CaPRe in LOwering Very hiGh TriglYcerides (TRILOGY 2)

Comparing Engage to PST for Late Life Depression

A Randomized Trial of Telemetry Compared With Unmonitored Floor Admissions in ED Patients With Low-Risk Chest Pain

Effects of Latin Dancing on Sleep Quality in Hispanic Cancer Survivors

UARK 2014-14: Phase II Prospective Evaluation of Bone Remodeling During Ixazomib Treatment

EluPro Antibiotic-Eluting BioEnvelope Registry

An Observational, Qualitative Study Assessing Eye Drop Administration

iMETX (Individualized Metabolic RX): a Pilot Study

Ixmyelocel-T Treatment of Patients With Osteonecrosis of the Femoral Head

Local Field Potentials Recorded From Deep Brain Stimulating (DBS) Electrodes

An Evaluation of Exenatide and Rosiglitazone in Subjects With Type 2 Diabetes Mellitus

Phase I Study of the Safety, Tolerance, and Pharmacokinetics of 9-[2-(Bispivaloyloxymethyl)Phosphonylmethoxyethyl]Adenine (Bis-POM PMEA; Adefovir Dipivoxil) in HIV-Infected Patients

Aspirin Or Warfarin To Prevent Stroke

Defining Normal Citrulline Levels as a Diagnostic Tool for Screening of Gastrointestinal Disease in Premature Infants

Lung Rehabilitation in Treating Patients With Chronic Obstructive Pulmonary Disease Who Are Undergoing Surgery for Lung Cancer

Veliparib in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Establishment of Genomic and Phenotypic Database for Niemann-Pick Disease, Type C

Arsenic Trioxide in Treating Patients With Urothelial Cancer

Probiotic Use in Children Undergoing Hematopoietic Stem Cell Transplantation (HSCT)

A Trial to Determine How Long Insulin and FDKP (the Molecule That Forms Technosphere Particles) Stays in the Lungs of Healthy Individuals After Inhalation of Technosphere® Insulin (TI) Powder Using Bronchoalveolar Lavage (BAL)

Oral and IV Baclofen in Adult Volunteers

Vaccine Therapy and GM-CSF in Treating Patients With Progressive Non-Hodgkin's Lymphoma

Respiratory-Swallow Coordination in Cardiothoracic Surgical Patients